110 related articles for article (PubMed ID: 30211813)
21. Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma.
Tarhini AA; Moschos SJ; Lin Y; Lin HM; Sander C; Yin Y; Venhaus R; Gajewski TF; Kirkwood JM
Melanoma Res; 2017 Aug; 27(4):342-350. PubMed ID: 28489678
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma.
Ellerhorst JA; Bedikian AY; Smith TM; Papadopoulos NE; Plager C; Eton O
Anticancer Drugs; 2002 Feb; 13(2):169-72. PubMed ID: 11901310
[TBL] [Abstract][Full Text] [Related]
23. A phase 2 study of tremelimumab in patients with advanced uveal melanoma.
Joshua AM; Monzon JG; Mihalcioiu C; Hogg D; Smylie M; Cheng T
Melanoma Res; 2015 Aug; 25(4):342-7. PubMed ID: 26050146
[TBL] [Abstract][Full Text] [Related]
24. Phase I evaluation of STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in dogs with spontaneous cancer.
London CA; Bear MD; McCleese J; Foley KP; Paalangara R; Inoue T; Ying W; Barsoum J
PLoS One; 2011; 6(11):e27018. PubMed ID: 22073242
[TBL] [Abstract][Full Text] [Related]
25. Expression of focal adhesion kinase in uveal melanoma and the effects of Hsp90 inhibition by 17-AAG.
Faingold D; Filho VB; Fernandes B; Jagan L; de Barros AM; Orellana ME; Antecka E; Burnier MN
Pathol Res Pract; 2014 Nov; 210(11):739-45. PubMed ID: 25041838
[TBL] [Abstract][Full Text] [Related]
26. A phase II study of the insulin-like growth factor type I receptor inhibitor IMC-A12 in patients with metastatic uveal melanoma.
Mattei J; Ballhausen A; Bassett R; Shephard M; Chattopadhyay C; Hudgens C; Tetzlaff M; Woodman S; Sato T; Patel SP
Melanoma Res; 2020 Dec; 30(6):574-579. PubMed ID: 32976223
[TBL] [Abstract][Full Text] [Related]
27. Ipilimumab activity in advanced uveal melanoma.
Khattak MA; Fisher R; Hughes P; Gore M; Larkin J
Melanoma Res; 2013 Feb; 23(1):79-81. PubMed ID: 23211837
[TBL] [Abstract][Full Text] [Related]
28. A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors.
Adjei AA; LoRusso P; Ribas A; Sosman JA; Pavlick A; Dy GK; Zhou X; Gangolli E; Kneissl M; Faucette S; Neuwirth R; Bózon V
Invest New Drugs; 2017 Feb; 35(1):47-58. PubMed ID: 27650277
[TBL] [Abstract][Full Text] [Related]
29. Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma.
Ott PA; Carvajal RD; Pandit-Taskar N; Jungbluth AA; Hoffman EW; Wu BW; Bomalaski JS; Venhaus R; Pan L; Old LJ; Pavlick AC; Wolchok JD
Invest New Drugs; 2013 Apr; 31(2):425-34. PubMed ID: 22864522
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors for first-line therapy and overall survival of metastatic uveal melanoma: The Princess Margaret Cancer Centre experience.
Nicholas MN; Khoja L; Atenafu EG; Hogg D; Quirt I; Butler M; Joshua AM
Melanoma Res; 2018 Dec; 28(6):571-577. PubMed ID: 30067547
[TBL] [Abstract][Full Text] [Related]
31. Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome.
Schuster R; Lindner M; Wacker F; Krössin M; Bechrakis N; Foerster MH; Thiel E; Keilholz U; Schmittel A
Melanoma Res; 2010 Jun; 20(3):191-6. PubMed ID: 20335820
[TBL] [Abstract][Full Text] [Related]
32. Beta-blockers exert potent anti-tumor effects in cutaneous and uveal melanoma.
Bustamante P; Miyamoto D; Goyeneche A; de Alba Graue PG; Jin E; Tsering T; Dias AB; Burnier MN; Burnier JV
Cancer Med; 2019 Dec; 8(17):7265-7277. PubMed ID: 31588689
[TBL] [Abstract][Full Text] [Related]
33. The HSP-RTK-Akt axis mediates acquired resistance to Ganetespib in HER2-positive breast cancer.
Eyermann CE; Haley JD; Alexandrova EM
Cell Death Dis; 2021 Jan; 12(1):126. PubMed ID: 33500390
[TBL] [Abstract][Full Text] [Related]
34. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma.
Pyrhönen S; Hahka-Kemppinen M; Muhonen T; Nikkanen V; Eskelin S; Summanen P; Tarkkanen A; Kivelä T
Cancer; 2002 Dec; 95(11):2366-72. PubMed ID: 12436444
[TBL] [Abstract][Full Text] [Related]
35. Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma.
Atkinson TM; Hay JL; Shoushtari A; Li Y; Paucar DJ; Smith SC; Kudchadkar RR; Doyle A; Sosman JA; Quevedo JF; Milhem MM; Joshua AM; Linette GP; Gajewski TF; Lutzky J; Lawson DH; Lao CD; Flynn PJ; Albertini MR; Sato T; Lewis K; Marr B; Abramson DH; Dickson MA; Schwartz GK; Carvajal RD
J Cancer Res Clin Oncol; 2017 Mar; 143(3):439-445. PubMed ID: 27921276
[TBL] [Abstract][Full Text] [Related]
36. Percutaneous Isolated Hepatic Perfusion as a Treatment for Isolated Hepatic Metastases of Uveal Melanoma: Patient Outcome and Safety in a Multi-centre Study.
Vogl TJ; Koch SA; Lotz G; Gebauer B; Willinek W; Engelke C; Brüning R; Zeile M; Wacker F; Vogel A; Radeleff B; Scholtz JE
Cardiovasc Intervent Radiol; 2017 Jun; 40(6):864-872. PubMed ID: 28144756
[TBL] [Abstract][Full Text] [Related]
37. Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma.
Cheng H; Terai M; Kageyama K; Ozaki S; McCue PA; Sato T; Aplin AE
Cancer Res; 2015 Jul; 75(13):2737-48. PubMed ID: 25952648
[TBL] [Abstract][Full Text] [Related]
38. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
[TBL] [Abstract][Full Text] [Related]
39. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma.
Kirkwood JM; Lorigan P; Hersey P; Hauschild A; Robert C; McDermott D; Marshall MA; Gomez-Navarro J; Liang JQ; Bulanhagui CA
Clin Cancer Res; 2010 Feb; 16(3):1042-8. PubMed ID: 20086001
[TBL] [Abstract][Full Text] [Related]
40. Uveal Melanoma Metastatic to the Liver: Chemoembolization With 1,3-Bis-(2-Chloroethyl)-1-Nitrosourea.
Gonsalves CF; Eschelman DJ; Thornburg B; Frangos A; Sato T
AJR Am J Roentgenol; 2015 Aug; 205(2):429-33. PubMed ID: 25905562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
